Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DAAN Biotherapeutics, founded in 2020 by CEO Dr. Byoung Chul Cho, is a Seoul-based biotechnology company pioneering innovative cancer treatments. Specializing in T-cell receptor (TCR)-based therapies, the company develops advanced immune cell therapies targeting EGFR mutations in lung cancer. In January 2024, DAAN Biotherapeutics secured $17.2 million in Series A funding from 11 investors, including Solasta Ventures and Atinum...
DAAN Biotherapeutics, founded in 2020 by CEO Dr. Byoung Chul Cho, is a Seoul-based biotechnology company pioneering innovative cancer treatments. Specializing in T-cell receptor (TCR)-based therapies, the company develops advanced immune cell therapies targeting EGFR mutations in lung cancer. In January 2024, DAAN Biotherapeutics secured $17.2 million in Series A funding from 11 investors, including Solasta Ventures and Atinum Investment. In February 2025, they signed an exclusive licensing agreement with LigaChem Biosciences to advance Antibody-Drug Conjugate (ADC) therapeutics.

List your booth number for exhibitions, ask us